GlassScriptPhysician profile
Oscar Urrea
NPI 1104893791
$3,165.83
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,154 · 2020: $196 · 2021: $732 · 2022: $1,033 · 2023: $51.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $51.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $51.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,130.26 | 2021-2023 | Vraylar |
| Alkermes, INC. | $570.86 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $394.54 | 2019 | |
| Sunovion Pharmaceuticals INC. | $348.49 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $176.35 | 2019-2020 | |
| Lundbeck LLC | $116.52 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $94.49 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.95 | 2020-2022 | |
| Indivior INC. | $54.81 | 2019 | |
| Allergan, INC. | $47.70 | 2019 | |
| Almatica Pharma LLC | $42.38 | 2022 | |
| Corium, LLC | $23.69 | 2022 | |
| Avanir Pharmaceuticals, INC. | $22.09 | 2019 | |
| Orexo US, INC. | $17.03 | 2021 | |
| Neurocrine Biosciences, INC. | $15.21 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $15.04 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Urrea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.